Telix CFO buys 2,071 shares under employee plan

Telix Pharmaceuticals’ Group CFO increased his direct stake through an AU employee share purchase plan allocation.

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd (TLX) reported that its Group Chief Financial Officer, Darren Charlton Smith, purchased 2,071 Ordinary Shares on September 7, 2026. The shares were acquired at 9.656 per share in Australian Dollars under the Employee Share Purchase Plan section of the company’s Equity Incentive Plan, bringing his direct holdings to 13,992 shares.

Insider Trade Summary

Net Buyer: 2,071 shares

Net Buy 1 txn

Insider Smith Darren Charlton

Role Group Chief Financial Officer

Bought 2,071 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1, F2	2,071	$9.656	$20K

Holdings After Transaction: Ordinary Shares — 13,992 shares (Direct)

Footnotes (2)

1. F1. Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.
2. F2. Purchase price is recorded in Australian Dollars.

Key Figures

Shares purchased: 2,071 shares Purchase price per share: 9.656 per share Shares held after transaction: 13,992 shares +2 more

5 metrics

Shares purchased 2,071 shares Ordinary Shares acquired on September 7, 2026

Purchase price per share 9.656 per share Price recorded in Australian Dollars for the September 7, 2026 purchase

Shares held after transaction 13,992 shares Direct ownership by the Group Chief Financial Officer following the purchase

Plan contribution period January 1, 2026 – June 30, 2026 Period of contributions to the AU ESPP used to allocate the purchased shares

Net buy shares 2,071 shares Net effect of reported transactions in this Form 4

Key Terms

Employee Share Purchase Plan, Equity Incentive Plan, AU ESPP, Ordinary Shares

4 terms

Employee Share Purchase Plan financial

"Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section"

A program that lets employees buy their employer’s stock, often through regular payroll deductions and sometimes at a discounted price or with matching contributions; think of it as a company-run savings plan that converts part of pay into ownership. It matters to investors because it can increase insider ownership and employee motivation, potentially affecting company performance, and can slightly change share supply when new stock is issued or sold.

Equity Incentive Plan financial

"under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AU ESPP financial

"contributions to the AU ESPP from January 1, 2026 - June 30, 2026"

Ordinary Shares financial

"Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TLX report for its Group CFO?

Telix Pharmaceuticals Ltd reported that Group Chief Financial Officer Darren Charlton Smith purchased 2,071 Ordinary Shares on September 7, 2026, under the Employee Share Purchase Plan section of the Equity Incentive Plan, at a price of 9.656 per share in Australian Dollars.

How many TLX shares does the Group CFO hold after this transaction?

After the reported purchase, Group Chief Financial Officer Darren Charlton Smith directly holds 13,992 Ordinary Shares of Telix Pharmaceuticals Ltd.

At what price were the TLX shares purchased in this Form 4 filing?

The 2,071 Telix Pharmaceuticals Ltd Ordinary Shares were purchased at a price of 9.656 per share, with the filing stating that the purchase price is recorded in Australian Dollars.

Was the TLX insider share purchase made under an employee plan?

Yes. The filing states the 2,071 Ordinary Shares were purchased under the Employee Share Purchase Plan section of Telix Pharmaceuticals Ltd’s Equity Incentive Plan, referred to as the "AU ESPP".

Was the TLX CFO’s transaction under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 trading plan box is not checked, and the footnotes describe the allocation under the AU ESPP, so no Rule 10b5-1 plan is reported for this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 07:20 PM Accepted by SEC EDGAR 09/14/2026 - 07:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Darren Charlton

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group Chief Financial Officer

2a. Foreign Trading Symbol
[TLX]

3. Date of Earliest Transaction (Month/Day/Year)
09/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/07/2026		P		2,071(1)	A	$9.656(2)	13,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.

2. Purchase price is recorded in Australian Dollars.

Remarks:

	/s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)